| Description: | The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival. |
|---|
| Link: | http://clinicaltrials.gov/ct2/show/study/NCT01306890 |
|---|---|
| Site: | Howard University Hospital |
| Principle Investigator: | Chiledum Ahaghotu, MD |